Pyxis Oncology Q2 net loss $17.3M; cash $157.2M funds into 2H 2026

Pyxis Oncology, Inc.

2024-Q2 EPS reported -$0.37 revenue$16,146,000

Net loss $17.3M ($0.29/shr) vs $15.9M ($0.41/shr) in Q2 2023; R&D spend $13.9M.
Cash, equivalents and short-term investments $157.2M as of June 30, 2024; runway into 2H 2026.
PYX-201 Phase 1: 72 subjects dosed; preliminary data (efficacy, safety, PK) expected fall 2024.
PYX-106 Phase 1: 33 subjects dosed; preliminary data (PK/PD) expected by year-end 2024.
Outstanding shares: 58,942,243 as of August 14, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.